LSA
VERV

Leonteq Securities AG’s Verve Therapeutics VERV Stock Holding History

Leonteq Securities AG’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-200
Closed -$3.87K – 1340
2022
Q4 		$3.87K Buy
+200
New +$5.3K ﹤0.01% 1153
2022
Q1 		– Sell
-250
Closed -$9.22K – 1344
2021
Q4 		$9.22K Buy
+250
New +$10.5K ﹤0.01% 1160

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Leonteq Securities AG's VERV Position: Q1 2023 in Review

Leonteq Securities AG sold out of Verve Therapeutics (VERV) in Q1 2023, closing a stake of 200 shares — an estimated $3.87K sold.

Leonteq Securities AG first reported a position in VERV in Q4 2021 and held it in 2 quarters. The position peaked at $9.22K in Q4 2021. 125 funds tracked by Wall St. Rank hold VERV as of Q1 2023.

  • Leonteq Securities AG reported no remaining Verve Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Leonteq Securities AG sold 200 Verve Therapeutics shares in Q1 2023, an estimated $3.87K.
  • Leonteq Securities AG first reported a position in Verve Therapeutics in Q4 2021 and held it in 2 quarters.
  • Leonteq Securities AG's Verve Therapeutics position peaked at $9.22K in Q4 2021.
  • 125 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2023.

Based on Leonteq Securities AG's 13F filing for Q1 2023, filed 11 Mar 2026.